Novartis International AG Says Deaths Linked to FDA's Iron Drug

WASHINGTON (Reuters) -- Severe kidney failure and some deaths have been reported in patients using Novartis AG's iron overload drug Exjade, the Food and Drug Administration said Tuesday. The problems with Exjade, which removes excess iron from certain organs in patients receiving blood transfusions, were found in post-marketing reports for the drug, which was approved in late 2005, the agency said.

Back to news